Document is current
Any future updates will be listed below
-
Authors
Zuo, Yantao
Solingapuram Sai, Kiran Kumar
Jazic, Aeva
Bansode, Avinash H.
Rose, Jed E.
Mukhin, Alexey G. http://orcid.org/0000-0002-7268-1322
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01DA044756)
- License Information
-
More Information
Article History
Received: 19 November 2023
Revised: 27 December 2023
Accepted: 3 January 2024
First Online: 15 January 2024
Competing interests
: AGM discloses grants from the National Institute on Drug Abuse and consulting for Rose Research Center LLC on the project funded by Philip Morris International, outside the submitted work. JER discloses grants from the National Institute on Drug Abuse, research support from Foundation for a Smoke-Free World, Philip Morris International, Altria Client Services, JUUL Labs, Otsuka Pharmaceutical, Swedish Match North America, Nicotine BRST LLC; consulting with JT International, SA; and consulting and patent purchase agreement with Philip Morris International for nicotine inhalation system patents, final payment 2014; patent applications filed for bupropion/zonisamide and related drug combinations. All other authors declare no competing interests.
